Generation of Forms of Fragment E with Differing Thrombin-binding Properties During Digestion of Fibrinogen by Plasmin

Overview

Journal Biochem J

Specialty Biochemistry

Date 1992 Feb 1

PMID 1531588

Authors

C A Goodwin

V V Kakkar

M F Scully

Affiliations

Soon will be listed here.

Abstract

Two principal forms of fragment E are generated upon digestion of fibrinogen by plasmin, according to the concentration of enzyme used. At a high concentration of plasmin (above 10 micrograms/ml), a form lacking fibrinopeptide A (FpA) at the N-terminus of the A alpha-chain was generated. This form of fragment E caused a dose-dependent increase in thrombin clotting times but had no measurable inhibitory activity towards thrombin cleavage of D-phenylalanyl-L-pipecolyl-L-arginine p-nitroanilide. At a low concentration of plasmin (less than 1 microgram/ml), fragment E containing 35-40% of the original amount of FpA was present in the terminal digest. The FpA-containing form of fragment E inhibited thrombin cleavage of fibrinogen, inhibited amidolytic activity and bound to the enzyme with an affinity 3-fold tighter than fibrinogen itself (Kd 4.1 +/- 0.3 microM as opposed to 12.7 +/- 1.8 microM). During digestion of fibrinogen at low plasmin concentration, up to 65% of the FpA was cleaved just subsequent to the progressive release of B beta-(1-42)-peptide, and the Arg-16-Gly-17 bond of the A alpha-chain became relatively stable towards plasmin action when present in fragment E (and possibly fragment Y). It is proposed that both forms of fragment E can inhibit clotting by binding to the fibrin(ogen)-recognition site (anion-binding exosite) of thrombin. The FpA-containing form of fragment E can also inhibit binding that occurs distal to the P1 site and thereby interfere with amidolysis of the peptide substrate. Our finding of a lability of the Arg-16-Gly-17 bond in the early phase of digestion may provide an alternative explanation of the increased FpA concentrations observed during thrombolytic therapy.

References

Olexa S, Budzynski A, Doolittle R, Cottrell B, Greene T . Structure of fragment E species from human cross-linked fibrin. Biochemistry. 1981; 20(21):6139-45. DOI: 10.1021/bi00524a035. View

Doolittle R . Fibrinogen and fibrin. Annu Rev Biochem. 1984; 53:195-229. DOI: 10.1146/annurev.bi.53.070184.001211. View

Lundblad R, Nesheim M, Straight D, Sailor S, Bowie J, Jenzano J . Bovine alpha- and beta-thrombin. Reduced fibrinogen-clotting activity of beta-thrombin is not a consequence of reduced affinity for fibrinogen. J Biol Chem. 1984; 259(11):6991-5. View

Scully M, Kakkar V . Structural features of fibrinogen associated with binding to chelated zinc. Biochim Biophys Acta. 1982; 700(1):130-5. DOI: 10.1016/0167-4838(82)90301-6. View

Marsh Jr H, Meinwald Y, Lee S, Scheraga H . Mechanism of action of thrombin on fibrinogen. Direct evidence for the involvement of phenylalanine at position P9. Biochemistry. 1982; 21(24):6167-71. DOI: 10.1021/bi00267a022. View

NUSSENZWEIG V, SELIGMANN M, PELMONT J, Grabar P . [The products of degradation of human fibrinogen by plasmin. I. Separation and physicochemical properties]. Ann Inst Pasteur (Paris). 1961; 100:377-89. View

Bailey K, BETTELHEIM F, Lorand L, MIDDLEBROOK W . Action of thrombin in the clotting of fibrinogen. Nature. 1951; 167(4241):233-4. DOI: 10.1038/167233a0. View

MIHALYI E, Weinberg R, Towne D, FRIEDMAN M . Proteolytic fragmentation of fibrinogen. I. Comparison of the fragmentation of human and bovine fibrinogen by trypsin or plasmin. Biochemistry. 1976; 15(24):5372-81. DOI: 10.1021/bi00669a025. View

Takagi T, Doolittle R . The amino acid sequences of those portions of human fibrinogen fragment E which are not included in the amino-terminal disulfide knot. Thromb Res. 1975; 7(5):813-8. DOI: 10.1016/0049-3848(75)90206-6. View

10.

Takagi T, Doolittle R . Amino acid sequence studies on plasmin-derived fragments of human fibrinogen: amino-terminal sequences of intermediate and terminal fragments. Biochemistry. 1975; 14(5):940-6. DOI: 10.1021/bi00676a010. View

11.

Gardlund B . Human fibrinogen--amino acid sequence of fragment E and of adjacent structures in the Aalpha and Bbeta -chains. Thromb Res. 1977; 10(5):689-702. DOI: 10.1016/0049-3848(77)90051-2. View

12.

Naski M, Shafer J . Alpha-thrombin-catalyzed hydrolysis of fibrin I. Alternative binding modes and the accessibility of the active site in fibrin I-bound alpha-thrombin. J Biol Chem. 1990; 265(3):1401-7. View

13.

Lord S, Byrd P, Hede K, Wei C, Colby T . Analysis of fibrinogen A alpha-fusion proteins. Mutants which inhibit thrombin equivalently are not equally good substrates. J Biol Chem. 1990; 265(2):838-43. View

14.

Scully M, Ellis V, Watahiki Y, Kakkar V . Activation of pro-urokinase by plasmin: non-Michaelian kinetics indicates a mechanism of negative cooperativity. Arch Biochem Biophys. 1989; 268(2):438-46. DOI: 10.1016/0003-9861(89)90311-1. View

15.

Kazura J, Wenger J, Salata R, Budzynski A, Goldsmith G . Modulation of polymorphonuclear leukocyte microbicidal activity and oxidative metabolism by fibrinogen degradation products D and E. J Clin Invest. 1989; 83(6):1916-24. PMC: 303912. DOI: 10.1172/JCI114098. View

16.

Bode W, Mayr I, Baumann U, Huber R, Stone S, Hofsteenge J . The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 1989; 8(11):3467-75. PMC: 401503. DOI: 10.1002/j.1460-2075.1989.tb08511.x. View

17.

Fenton 2nd J . Thrombin interactions with hirudin. Semin Thromb Hemost. 1989; 15(3):265-8. DOI: 10.1055/s-2007-1002718. View

18.

Maraganore J, Chao B, Joseph M, Jablonski J, Ramachandran K . Anticoagulant activity of synthetic hirudin peptides. J Biol Chem. 1989; 264(15):8692-8. View

19.

Ni F, Meinwald Y, Vasquez M, Scheraga H . High-resolution NMR studies of fibrinogen-like peptides in solution: structure of a thrombin-bound peptide corresponding to residues 7-16 of the A alpha chain of human fibrinogen. Biochemistry. 1989; 28(7):3094-105. DOI: 10.1021/bi00433a053. View

20.

Owen J, Friedman K, Grossman B, Wilkins C, Berke A, Powers E . Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood. 1988; 72(2):616-20. View